Item request has been placed!
×
Item request cannot be made.
×
Processing Request
SAMD1 suppresses epithelial-mesenchymal transition pathways in pancreatic ductal adenocarcinoma.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101183755 Publication Model: eCollection Cited Medium: Internet ISSN: 1545-7885 (Electronic) Linking ISSN: 15449173 NLM ISO Abbreviation: PLoS Biol Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science, [2003]-
- Subject Terms:
- Abstract:
Pancreatic ductal adenocarcinoma (PDAC) poses a significant threat due to its tendency to evade early detection, frequent metastasis, and the subsequent challenges in devising effective treatments. Processes that govern epithelial-mesenchymal transition (EMT) in PDAC hold promise for advancing novel therapeutic strategies. SAMD1 (SAM domain-containing protein 1) is a CpG island-binding protein that plays a pivotal role in the repression of its target genes. Here, we revealed that SAMD1 acts as a repressor of genes associated with EMT. Upon deletion of SAMD1 in PDAC cells, we observed significantly increased migration rates. SAMD1 exerts its effects by binding to specific genomic targets, including CDH2, encoding N-cadherin, which emerged as a driver of enhanced migration upon SAMD1 knockout. Furthermore, we discovered the FBXO11-containing E3 ubiquitin ligase complex as an interactor and negative regulator of SAMD1, which inhibits SAMD1 chromatin-binding genome-wide. High FBXO11 expression in PDAC is associated with poor prognosis and increased expression of EMT-related genes, underlining an antagonistic relationship between SAMD1 and FBXO11. In summary, our findings provide insights into the regulation of EMT-related genes in PDAC, shedding light on the intricate role of SAMD1 and its interplay with FBXO11 in this cancer type.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Simon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- References:
Nature. 2023 Aug;620(7973):402-408. (PMID: 37532929)
Clin Transl Med. 2019 Jan 15;8(1):2. (PMID: 30645701)
J Biol Chem. 2007 Jan 19;282(3):1797-804. (PMID: 17098746)
Sci Rep. 2021 Mar 15;11(1):6047. (PMID: 33723286)
Mol Cell. 2005 Sep 16;19(6):857-64. (PMID: 16140033)
Cancer Cell. 2018 Mar 12;33(3):495-511.e12. (PMID: 29502954)
Cell Signal. 2013 Dec;25(12):2856-62. (PMID: 24044921)
Comput Struct Biotechnol J. 2021 May 14;19:3027-3033. (PMID: 34136100)
Sci Adv. 2021 May 12;7(20):. (PMID: 33980486)
Nucleic Acids Res. 2023 Jan 25;51(2):574-594. (PMID: 36537216)
Nature. 2010 Apr 15;464(7291):1082-6. (PMID: 20393567)
Cancers (Basel). 2022 Feb 12;14(4):. (PMID: 35205666)
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. (PMID: 28407145)
Int J Cancer. 2008 Jan 1;122(1):71-7. (PMID: 17721921)
Biomed Res Int. 2017;2017:2646148. (PMID: 29379795)
Cancer Lett. 2015 Jun 28;362(1):70-82. (PMID: 25827072)
Genome Biol. 2009;10(3):R25. (PMID: 19261174)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Biology (Basel). 2022 Apr 06;11(4):. (PMID: 35453756)
Genes Dev. 2011 May 15;25(10):1010-22. (PMID: 21576262)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33. (PMID: 15217949)
Mol Cell. 2013 Oct 10;52(1):25-36. (PMID: 24076218)
Nat Rev Dis Primers. 2016 Apr 21;2:16022. (PMID: 27158978)
Therap Adv Gastroenterol. 2013 Jul;6(4):321-37. (PMID: 23814611)
Carcinogenesis. 2009 Feb;30(2):238-48. (PMID: 19056927)
Nature. 2012 Sep 6;489(7414):75-82. (PMID: 22955617)
Nature. 2012 Sep 6;489(7414):57-74. (PMID: 22955616)
Genome Biol. 2004;5(10):R80. (PMID: 15461798)
Mol Cell Biol. 2000 Mar;20(6):2108-21. (PMID: 10688657)
Cell Cycle. 2015;14(4):481-7. (PMID: 25607528)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Genome Biol. 2008;9(9):R137. (PMID: 18798982)
Nature. 2002 Apr 18;416(6882):703-9. (PMID: 11961546)
Nature. 2012 Jan 5;481(7379):90-3. (PMID: 22113614)
Function (Oxf). 2022 May 23;3(4):zqac027. (PMID: 35774589)
Mol Cell. 2010 May 28;38(4):576-89. (PMID: 20513432)
Int J Dev Biol. 2004;48(5-6):463-76. (PMID: 15349821)
Hum Cell. 2022 Jul;35(4):1174-1191. (PMID: 35437704)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Protein Sci. 2017 Oct;26(10):2092-2097. (PMID: 28691247)
Nature. 2017 Sep 14;549(7671):287-291. (PMID: 28869966)
Genome Res. 2022 Nov-Dec;32(11-12):1967-1980. (PMID: 36351771)
Cells. 2019 Sep 20;8(10):. (PMID: 31547193)
Nat Biotechnol. 2010 May;28(5):495-501. (PMID: 20436461)
Blood. 2021 Jan 14;137(2):155-167. (PMID: 33156908)
Cancer. 2022 Dec 15;128(24):4251-4284. (PMID: 36301149)
Nat Genet. 2013 Oct;45(10):1113-20. (PMID: 24071849)
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W187-91. (PMID: 24799436)
BMC Cancer. 2013 Oct 25;13:496. (PMID: 24156409)
Mol Cell. 2015 Mar 19;57(6):957-970. (PMID: 25684206)
Mol Cell. 2013 Mar 28;49(6):1159-66. (PMID: 23478441)
Genes (Basel). 2023 Apr 18;14(4):. (PMID: 37107696)
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. (PMID: 34723319)
Nucleic Acids Res. 2022 Jul 5;50(W1):W345-W351. (PMID: 35446428)
Cell Syst. 2018 Sep 26;7(3):310-322.e4. (PMID: 30145115)
Sci Rep. 2023 Feb 21;13(1):3000. (PMID: 36810619)
Nat Rev Gastroenterol Hepatol. 2011 Dec 20;9(2):77-87. (PMID: 22183185)
Cell. 2016 Jun 30;166(1):21-45. (PMID: 27368099)
- Accession Number:
0 (Cadherins)
0 (F-Box Proteins)
0 (Intracellular Signaling Peptides and Proteins)
0 (SAMD1 protein, human)
0 (Receptors, LDL)
- Publication Date:
Date Created: 20240813 Date Completed: 20240823 Latest Revision: 20240827
- Publication Date:
20250114
- Accession Number:
PMC11343471
- Accession Number:
10.1371/journal.pbio.3002739
- Accession Number:
39137238
No Comments.